Sulfonylureas

For medical students2 min readUpdated 2026-10-10

Sulfonylureas are a major class of synthetic oral hypoglycemic agents used in the management of type 2 diabetes mellitus. Their primary mechanism involves stimulating endogenous insulin secretion by the pancreas.

GenerationsDivided into 1st and 2nd generations (2nd generation is clinically preferred)

MechanismBlockade of ATP-sensitive potassium ($K_{ATP}$) channels in $\beta$-cells

Plasma bindingHigh degree of binding to serum albumins

ComplicationsRisk of secondary failure/resistance after ~3 years of therapy

Classification and Generations

In modern clinical practice, these medications are divided into two main categories:

1st Generation: Includes compounds such as carbutamide, tolazamide, tolbutamide, and chlorpropamide.
2nd Generation: Represented by more potent agents, among which are glibenclamide (glyburide), gliclazide, glipizide, and gliquidone.

Currently, there is a clear clinical preference for second-generation agents due to their superior potency, safety, and pharmacokinetic profiles.

Mechanism of Hypoglycemic Action

The pharmacological effect is multifaceted, but the primary driver is the stimulation of endogenous insulin secretion. The pancreatic mechanism follows this specific sequence:

The drug binds to a specific receptor (~140 kDa) on the membrane of the pancreatic islet $\beta$-cell.
This leads to the closure of ATP-dependent $K^+$ channels, halting the efflux of potassium ions.
Intracellular potassium accumulation causes depolarization of the cell membrane.
Voltage-gated $Ca^{2+}$ channels open, allowing calcium ions to rapidly enter the cytoplasm.
The rise in intracellular calcium triggers the exocytosis of preformed insulin vesicles.
Additionally, extrapancreatic and sensitizing effects occur: $\beta$-cell sensitivity to glucose is restored, insulin receptor density and affinity in peripheral tissues increase, and intracellular signaling pathways are enhanced.

Pharmacokinetics and Safety

Drugs in this group possess important pharmacokinetic characteristics:

Appetite: They can stimulate appetite, which can counteract strict dietary control in diabetes management.
Protein Binding: They exhibit a high degree of binding to plasma albumin, creating a risk of drug-drug interactions with NSAIDs and oral anticoagulants that compete for the same binding sites.
Pregnancy: Active substances cross the placental barrier, requiring extreme caution if used during pregnancy.

Therapeutic Challenges and Risks

Long-term sulfonylurea therapy is associated with several clinical challenges:

Selectivity Issue: Potassium channel blockade affects not only pancreatic $\beta$-cells but also cardiomyocytes and vascular smooth muscle cells (angiomyocytes). Over time, this may increase cardiovascular mortality risks.
Secondary Failure: A subset of patients develops a progressive loss of glycemic control (secondary resistance) after approximately three years of regular therapy.

Frequently asked questions

What adverse effects are typical for sulfonylureas?

The hallmark adverse effects of sulfonylureas include hypoglycemia, increased appetite, and weight gain.

Hypoglycemia is the primary therapeutic risk, the likelihood of which increases significantly with advanced age.
Weight gain is an undesirable effect because diabetes management relies heavily on caloric and dietary control.
Cardiovascular risks — long-term administration may increase cardiovascular mortality due to non-selective potassium channel blockade in cardiomyocytes and vascular smooth muscle cells.

Additionally, secondary resistance develops in some patients after 3 years of ongoing therapy.

What are the absolute contraindications for sulfonylureas?

Standard contraindications include diabetic ketoacidosis, severe hepatic impairment, pregnancy, and lactation. Renal failure is also generally considered a contraindication, though certain agents like gliclazide, glimepiride, and gliquidone may be used with caution and dose adjustments.

Because these drugs cross the placental barrier, their use during pregnancy requires extreme caution. Glibenclamide should be avoided in the setting of acute coronary syndrome.

What are the pathways of elimination for sulfonylureas?

For glimepiride, elimination pathways include both the renal and hepatobiliary routes.

The drug is metabolized by the liver into active metabolites (primarily carboxylated and hydroxylated derivatives), which are then excreted via the kidneys and feces. The elimination half-life of glimepiride is approximately 5–8 hours.

What is the primary pancreatic mechanism of action of sulfonylureas?

The drug binds to a receptor on the $\beta$-cell membrane, blocks ATP-sensitive potassium channels, induces membrane depolarization, opens calcium channels, and triggers the exocytosis of endogenous insulin.

Why can sulfonylureas cause significant drug interactions?

They have a high degree of binding to plasma albumin, meaning they can compete for protein-binding sites with other drugs such as NSAIDs or warfarin.

What is the issue regarding the selectivity of these drugs?

These medications block potassium channels not only in the pancreas but also in blood vessels and the heart, elevating cardiovascular risks during long-term use.

What is secondary resistance (failure)?

It is the progressive decline in therapeutic efficacy observed in some patients after three years of regular sulfonylurea therapy.

Go deeper

Complete list of 1st generation agents
Complete list of 2nd generation agents
Extrapancreatic effects and post-receptor signaling pathways
Mechanisms of transplacental drug transfer
Impact of potassium channel blockade on cardiomyocytes and vascular smooth muscle cells